Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name Disitamab vedotin
Synonyms
Therapy Description

Disitamab vedotin (RC48) is an antibody-drug conjugate comprising a monoclonal antibody that targets HER2 (Hertuzumab) linked to the cytotoxic drug MMAE, which delivers the cytotoxic agent to HER2-expressing tumor cells, potentially resulting in increased cell death (PMID: 27509865, PMID: 31877330).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Disitamab vedotin RC48|Hertuzumab-vc-MMAE|RC-48 HER2 (ERBB2) Antibody 72 Disitamab vedotin (RC48) is an antibody-drug conjugate comprising a monoclonal antibody that targets HER2 (Hertuzumab) linked to the cytotoxic drug MMAE, which delivers the cytotoxic agent to HER2-expressing tumor cells, potentially resulting in increased cell death (PMID: 27509865, PMID: 31877330).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06157892 Phase Ib/II Disitamab vedotin + Tucatinib Disitamab vedotin A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors Recruiting USA 0
NCT06003231 Phase II Disitamab vedotin A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 Recruiting USA | CAN | AUS 0
NCT04879329 Phase II Disitamab vedotin Disitamab vedotin + Pembrolizumab A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 Recruiting USA | GBR | CAN | AUS 4


Additional content available in CKB BOOST